Form 4: C4 Therapeutics CMO Sells 10,000 Shares

C4 Therapeutics' Chief Medical Officer, Leonard Reyno, reported the sale of 10,000 shares of common stock at $2.22 per share.

Summary

• Leonard Reyno, Chief Medical Officer of C4 Therapeutics, Inc. (CCCC), reported a transaction involving the company's common stock.
• The transaction occurred on January 16, 2026.
• Mr. Reyno disposed of 10,000 shares of common stock.
• The shares were sold at a price of $2.22 per share.
• Following this transaction, Mr. Reyno beneficially owns 156,382 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the transaction was conducted under a Rule 10b5-1 plan, which suggests a pre-planned, non-discretionary sale, often for personal financial management rather than a reaction to new company-specific information. The amount sold is also relatively small.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, which suggests the sale was pre-scheduled and not based on new, undisclosed material information, mitigating potential negative interpretations of insider selling.

Negatives

• An insider, the Chief Medical Officer, sold shares, which can sometimes be interpreted by the market as a signal of reduced confidence in the company's near-term prospects, despite the 10b5-1 plan.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide specific industry context or trends beyond the company's stock activity.

Stakeholder Impact

• Shareholders may interpret the insider sale as a minor negative signal, though the 10b5-1 plan mitigates concerns about the timing of the sale.

Key Dates

Keywords

C4 Therapeutics, CCCC, insider trading, Form 4, stock sale, beneficial ownership, Leonard Reyno, Chief Medical Officer, 10b5-1 plan